Abstract：
BACKGROUND: Liver transplantation (LT) is a unique and effective method for treating end-stage liver diseases and acute liver failure, bringing hope to many patients with liver cancer. LT is currently widely used in the treatment of liver diseases. However, there have been no patients with liver cancer who have undergone ABO-incompatible (ABOi) LT after treatment with the programmed cell death protein 1 (PD-1) inhibitor reported in the literature.
METHODS: A patient with liver cancer who received sintilimab injection, an anti-PD1 therapy, before LT was admitted in the transplantation centre. This patient underwent ABOi LT. The perioperative treatment strategy of this patient was reported. A desensitisation protocol was conducted urgently for the patient before operation, and the immunosuppression programme of LT was adjusted. After operation, isoagglutinin titer and liver function indicators were strictly monitored. The patient recovered well after operation, and no sign of rejection reaction was observed.
CONCLUSIONS: We reported a patient with hepatocellular carcinoma (HCC) who received PD-1 inhibitor treatment before operation and successfully underwent ABOi LT. The present case report provides novel insights into the perioperative management of utilizing PD-1 inhibitors prior to ABOi LT in patients diagnosed with hepatocellular carcinoma (HCC).
METHODS: A patient with liver cancer who received sintilimab injection, an anti-PD1 therapy, before LT was admitted in the transplantation centre. This patient underwent ABOi LT. The perioperative treatment strategy of this patient was reported. A desensitisation protocol was conducted urgently for the patient before operation, and the immunosuppression programme of LT was adjusted. After operation, isoagglutinin titer and liver function indicators were strictly monitored. The patient recovered well after operation, and no sign of rejection reaction was observed.
CONCLUSIONS: We reported a patient with hepatocellular carcinoma (HCC) who received PD-1 inhibitor treatment before operation and successfully underwent ABOi LT. The present case report provides novel insights into the perioperative management of utilizing PD-1 inhibitors prior to ABOi LT in patients diagnosed with hepatocellular carcinoma (HCC).
摘要：
背景：肝移植（LT）是治疗终末期肝病和急性肝衰竭的独特而有效的方法，给许多肝癌患者带来希望。LT目前广泛用于肝脏疾病的治疗。然而,报道了少数肝癌患者在使用程序性细胞死亡蛋白1(PD-1)抑制剂后出现ABO不相容型(ABOi)LT的病例.
方法：一名肝癌患者接受辛替利玛注射液，抗PD1治疗,在LT进入移植中心之前。该患者接受了ABOiLT。报告了该患者的围手术期治疗策略。术前紧急对患者进行了脱敏方案，并调整了LT的免疫抑制方案。手术后,严格监测等凝集素滴度和肝功能指标。病人术后恢复良好,没有观察到排斥反应的迹象。
结论：我们报道了1例肝细胞癌（HCC）患者术前接受PD-1抑制剂治疗并成功接受ABOiLT。本病例报告为诊断为肝细胞癌（HCC）的患者在ABOiLT之前利用PD-1抑制剂的围手术期管理提供了新的见解。
方法：一名肝癌患者接受辛替利玛注射液，抗PD1治疗,在LT进入移植中心之前。该患者接受了ABOiLT。报告了该患者的围手术期治疗策略。术前紧急对患者进行了脱敏方案，并调整了LT的免疫抑制方案。手术后,严格监测等凝集素滴度和肝功能指标。病人术后恢复良好,没有观察到排斥反应的迹象。
结论：我们报道了1例肝细胞癌（HCC）患者术前接受PD-1抑制剂治疗并成功接受ABOiLT。本病例报告为诊断为肝细胞癌（HCC）的患者在ABOiLT之前利用PD-1抑制剂的围手术期管理提供了新的见解。
